Dorzolamide
- Generic Name
- Dorzolamide
- Brand Names
- Cosopt, Trusopt
- Drug Type
- Small Molecule
- Chemical Formula
- C10H16N2O4S3
- CAS Number
- 120279-96-1
- Unique Ingredient Identifier
- 9JDX055TW1
- Background
Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects. First marketed in 1995, dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt or in combination with timolol as Cosopt PF.
- Indication
Dorzolamide is indicated for the management of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It can also be used in combination with timolol for the same indication in patients who are insufficiently responsive to ophthalmic beta-blockers.
Its pre-operative use was also investigated to prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension
Equivalence Study of Dorzolamide 2% Eye Drops Solution
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2010-02-12
- Lead Sponsor
- Alfred E. Tiefenbacher (GmbH & Co. KG)
- Target Recruit Count
- 32
- Registration Number
- NCT00878917
- Locations
- 🇩🇪
Department of Opthalmology, Johannes-Gutenberg University Mainz, Mainz, Rheinland-Pfalz, Germany
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
- Conditions
- Glaucoma
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Massachusetts Eye and Ear Infirmary
- Target Recruit Count
- 21
- Registration Number
- NCT00824824
- Locations
- 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 140
- Registration Number
- NCT00822081
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 140
- Registration Number
- NCT00822055
1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 6
- Registration Number
- NCT00767481
Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 200
- Registration Number
- NCT00761995
- Locations
- 🇮🇳
Alcon Laboratories, India, Bangalore, India
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 44
- Registration Number
- NCT00716586
- Locations
- 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States
Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2008-05-08
- Lead Sponsor
- Northwestern Ophthalmic Institute S.C.
- Target Recruit Count
- 120
- Registration Number
- NCT00675207
- Locations
- 🇺🇸
Northwestern Ophthalmic Institute S.C., Glenview, Illinois, United States
Pharmacological Intervention in Diabetic Retinopathy
- Conditions
- Diabetic Retinopathy
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2010-12-29
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 87
- Registration Number
- NCT00619034
- Locations
- 🇩🇰
Department of Ophthalmology, Aarhus, Denmark
Circadian Rhythms of Aqueous Humor Dynamics in Humans
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT00572936
- Locations
- 🇺🇸
University of Nebraska Medical Center, Department of Ophthalmolgy and Visual Sciences, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.